โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Nexavar

sorafenib
Carcinoma, Hepatocellular;Carcinoma, Renal Cell
โœ… Authorised
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hรผrthle cell) thyroid carcinoma, refractory to radioactive iodine.

โš ๏ธ Patient safety

No

โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.